Mohty M, Olive D, Gaugler B
Laboratoire d'Immunologie des Tumeurs, Institut Paoli-Calmettes, Université de la Méditerranée, Marseille, France.
Leukemia. 2002 Nov;16(11):2197-204. doi: 10.1038/sj.leu.2402710.
Dendritic cells (DCs) are a system of potent antigen-presenting cells (APCs) specialized to initiate primary immune responses. DCs are considered important elements in the induction of specific antitumor cytotoxic effectors. At present, because of potential therapeutic implications, the critical role of DCs in cancer patients is under intensive investigation. Interactions between DCs and acute myeloid leukemia cells represent an attractive model for the study of DC physiology. Moreover, DCs can be a valuable therapeutic tool for the adjuvant treatment of leukemic patients. However, DC subsets in vivo may also be affected by leukemogenesis and may contribute to the escape of leukemia from immune control. The aim of this review is to shed further light on this paradoxical picture where the line between immune tolerance and immune defense is narrow.
树突状细胞（DCs）是一种强大的抗原呈递细胞（APCs）系统，专门用于启动初次免疫反应。DCs被认为是诱导特异性抗肿瘤细胞毒性效应器的重要因素。目前，由于潜在的治疗意义，DCs在癌症患者中的关键作用正在深入研究中。DCs与急性髓系白血病细胞之间的相互作用是研究DC生理学的一个有吸引力的模型。此外，DCs可以成为白血病患者辅助治疗的有价值的治疗工具。然而，体内的DC亚群也可能受到白血病发生的影响，并可能导致白血病逃避免疫控制。这篇综述的目的是进一步阐明这种矛盾的情况，即免疫耐受和免疫防御之间的界限很窄。
